ADIPOQ and metabolic syndrome: Makni et al [30] in another cross-sectional study of obese children (mean age 13.7 ± 1.3 years), investigated the efficacy of HOMA-Adiponectin and HOMA-IR in assessing insulin resistance classified according to metabolic syndrome diagnosis.